PARP1 and cancer: Ablation of either PARP1/2 or PARP3 function supressed pRPA32 foci when the TP53 mutated cancer cell lines C33A, MBA-MD-468, SKOV-3 and NCI-H1299 were treated with siENDOD1 (Supplementary Fig. 6a-b).